|
已读[62]
发布： 2014/04/01 09:19:55
传闻:常山药业 (300255 股吧,行情,资讯,主力买卖)重磅化药“达肝素钠”原料药和注射液,审评状态目前已重新变成“在审批”,该产品有望在二季度获批,实现国内首...
|
|
|
|
|
已读[62]
发布： 2014/04/01 09:19:51
肝素钠(注射级) 148,228,643.60 117,449,912.29 20.76% -33.14% -35.2% 2.52%低分子量肝素钙 428,092,116.27 84,303,724.92 80.31% 47.81%...
|
|
|
|
|
已读[59]
发布： 2014/04/01 09:19:48
普通肝素钠原料药业绩出现下滑,实现收入2.175亿元,较上年同期下降14.77%,销量为8968.44亿单位,较上年同期下降10.66%,但依诺肝素钠原料药取得良好的成绩,实现收入...
|
|
|
|
|
已读[58]
发布： 2014/04/01 09:19:44
传闻:常山药业 (300255)重磅化药“达肝素钠”原料药和注射液,审评状态目前已重新变成“在审批”,该产品有望在二季度获批,实现国内首仿。 传闻:国家发改委近日...
|
|
|
|
|
已读[65]
发布： 2014/04/01 09:19:41
传闻:常山药业 (300255)重磅化药“达肝素钠”原料药和注射液,审评状态目前已重新变成“在审批”,该产品有望在二季度获批,实现国内首仿。 传闻:国家发改委近日...
|
|
|
|
|
已读[52]
发布： 2014/04/01 09:19:38
常山药业(300255 ):重磅化药“达肝素钠”原料药和注射液,审评状态目前已重新变成“在审批”,该产品有望在二季度获批,实现国内首仿。 从科大讯飞(002230 ):...
|
|
|
|
|
已读[54]
发布： 2014/04/01 09:19:34
万邦医药是国内最大的肝素钠注射剂生产商,也是国内领先的低分子肝素注射剂生产商。控股赛诺康,保证了肝素钠原料药的稳定供应,降低了原料药的采购成本。在控股赛诺...
|
|
|
|
|
已读[39]
发布： 2014/04/01 09:19:30
The Globe and Mail Dr. Devereaux also stressed that these findings do not relate to prescribing a blood thinner like heparin after surgery to prevent blood clots, and that practice should continue. The research, published in the New England Journal of Medicine, was ... and more »
|
|
|
|
|
已读[36]
发布： 2014/04/01 09:19:26
RedOrbit With MPS III B, accumulations of heparin sulfate in the tissues are not eliminated and the accumulation causes damage to multiple organs, including the brain. “Cell therapy has recently received attention as a potential treatment for lysosomal storage ...
|
|
|
|
|
已读[35]
发布： 2014/04/01 09:19:23
CBC.ca (blog) ... risk having more frequent seizures. Earlier this year, McGill University Health Centre hospitals in Montreal reportedly ran out of a medication called protamine, an essential drug used in heart surgery to reverse the effects of a blood thinner ...
|
|
|
« 上一页 |
查看结果1821-1830共2625
|
下一页 »
|
|
